Feshchenko YuI Melnyk VM Novozhilova IO Lyrnyk SV The mortality of patients with tuberculosis: structure, dynamics and peculiarities in epidemic period Ukr Pulmonol J 2009 3 5-9 
Nikolayevskyy VV Brown TJ Bazhora YI Asmolov AA Balabanova YM Drobniewski FA Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine Clin Microbiol Infect 2007 13 129-138 
Atun R Olynik I Resistance to implementing policy change: the case of Ukraine Bulletin of World Health Organization 2008 86 147-154 
Batdelger D Dandii D Jirathitikal V Bourinbaiar AS Open label trial of therapeutic hepatitis B vaccine V-5 Immunitor (V5) delivered by oral route Lett Drug Design Discovery 2007 4 540-544 
Batdelger D Dandii D Jirathitikal V Bourinbaiar AS Open label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C Vaccine 2008 26 2733-2737 
Batdelger D Dandii D Dahgwahdorj Ya Erdenetsogt E Oyunbileg J Tsend N Bayarmagnai B Jirathitikal V Bourinbaiar AS Clinical experience with therapeutic vaccines designed for patients with hepatitis Curr Pharm Design 2009 15 1159-1171 
Arjanova OV Prihoda ND Yurchenko LV Sokolenko NI Frolov VM Tarakanovskaya MG Jirathitikal V Bourinbaiar AS Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis J Vaccin Vaccinat 2010 1 103 
Arjanova OV Prihoda ND Yurchenko LV Sokolenko NI Frolov VM Tarakanovskaya MG Batdelger D Jirathitikal V Bourinbaiar AS Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV co-infected TB Immunotherapy in press
Reitman S Frankel S A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases Am J Clin Pathol 1957 28 56-63 
Ostrovski&#301; VK Asanov BM Iangolenko DV Some blood indices and the leukocytic index of intoxication in tuberculosis, pneumonias, abscesses, and cancer of the lung Probl Tuberk Bolezn Legk 2005 3 43-46 
Zaitzeva SI Matveeva SL Gerasimova TG Pashkov YN Butov DA Pylypchuk VS Frolov VM Kutsyna GA Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo Clin Microbiol Infect 2009 15 1154-1162 
Veenstra H Baumann R Carroll NM Lukey PT Kidd M Beyers N Bolliger CT van Helden PD Walzl G Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders Clin Exp Immunol 2006 145 252-260 
Saukkonen JJ Cohn DL Jasmer RM Schenker S Jereb JA Nolan CM Peloquin CA Gordin FM Nunes D Strader DB Bernardo J Venkataramanan R Sterling TR ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee An official ATS statement: hepatotoxicity of antituberculosis therapy Am J Respir Crit Care Med 2006 174 935-952 
Vasantha M Gopi PG Subramani R Weight gain in patients with tuberculosis treated under directly observed treatment short-course (DOTS) Indian J Tuberc 2009 56 5-9 
Yew WW Leung CC Prognostic significance of early weight gain in underweight patients with tuberculosis Am J Respir Crit Care Med 2006 174 236-237 
Majumdar A Kamble PD Harinath BC Detection of circulating free and immune-complexed antigen in pulmonary tuberculosis using cocktail of antibodies to Mycobacterium tuberculosis excretory secretory antigens by peroxidase enzyme immunoassay Indian J Tuberc 2010 57 67-74 
Vilaplana C Montan&#233; E Pinto S Barriocanal AM Domenech G Torres F Cardona PJ Costa J Double-blind, randomized, placebo-controlled Phase I clinical trial of the therapeutical antituberculous vaccine RUTI Vaccine 2010 28 1106-1116 
Stanford J Stanford C Grange J Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis Front Biosci 2004 9 1701-1719 
Zhao G-R Feng D-H A systematic review of inactivated Mycobacterium phlei injection for adjunctive treatment of drug resistant pulmonary tuberculosis Pharm J Chin PLA 2009 25 361-364 
Nyasulu PS Role of adjunctive Mycobacterium w immunotherapy for tuberculosis J Exp Clin Med 2010 2 123-129 
Svistunova AS Pinegin BV Selitskaia RP Arshinova SS Klimova EG Andronova TM Batyrov FA Simonova AV The use of immunomodulator likopid in the combined treatment pulmonary tuberculosis Probl Tuberk 2002 3 21-25 
Lei JP Xiong GL Hu QF Li Y Zong PL Tu SH Tu RY Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug-resistant tuberculosis Zhonghua Yu Fang Yi Xue Za Zhi 2008 42 86-89 
Kaufmann SH Is the development of a new tuberculosis vaccine possible? Nat Med 2000 6 955-960 
Kato S Tokunaga O Yoshiyama T Analysis of Koch's phenomenon by BCG vaccination with the multi-puncture method in Japan Kekkaku 2010 85 782-785 
Repique CJ Li A Collins FM Morris SL DNA Immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge Infect Immun 2002 70 3318-3323 
Moreira AL Tsenova L Aman MH Bekker L-G Freeman S Mangaliso B Schr&#246;der U Jagirdar J Rom WN Tovey MG Freedman VH Kaplan G Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice Infect Immun 2002 70 2100-2107 
Basaraba RJ Izzo AA Brandt L Orme IM Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations Vaccine 2006 24 280-286 
Radaeva TV Nikonenko BV Kapina MA Mishchenko VV Apt AS Experimental approaches to designing vaccines against tuberculous infection reactivation Probl Tuberk Bolezn Legk 2006 5 45-48 
Cruz A Fraga AG Fountain JJ Rangel-Moreno J Torrado E Saraiva M Pereira DR Randall TD Pedrosa J Cooper AM Castro AG Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis J Exp Med 2010 207 1609-1616 
Derrick SC Perera LP Dheenadhayalan V Yang A Kolibab K Morris SL The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis Vaccine 2008 26 6092-6098 
Roth AE Benn CS Ravn H Rodrigues A Lisse IM Yazdanbakhsh M Whittle H Aaby P Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau BMJ 2010 340 c671 
Silin DS Lyubomska OV Jirathitikal V Bourinbaiar AS Oral vaccination: where we are? Expert Opin Drug Deliv 2007 4 323-340 
Zaitzeva SI Matveeva SL Gerasimova TG Pashkov YuN Butov DA Pylypchuk VS Frolov VM Kutsyna GA Efficacy and safety of phytoconcentrate Dzherelo (Immunoxel) in treatment of patients with multi-drug resistant TB (MDR-TB) in comparison to standard chemotherapy Res J Med Sci 2009 3 36-41 
Churchyard GJ Kaplan G Fallows D Wallis RS Onyebujoh P Rook GA Advances in immunotherapy for tuberculosis treatment Clin Chest Med 2009 30 769-782 
Thaiss CA Kaufmann SH Toward novel vaccines against tuberculosis: current hopes and obstacles Yale J Biol Med 2010 83 209-215 
Dheda K Schwander SK Zhu B van Zyl-Smit RN Zhang Y The immunology of tuberculosis: from bench to bedside Respirology 2010 15 433-450 
